Spots Global Cancer Trial Database for A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

Official Title: A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma

Study ID: NCT01221571

Conditions

Hodgkin Lymphoma

Interventions

AFM 13

Study Description

Brief Summary: The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma.

Detailed Description: Study Objectives: The overall objective of this study is to determine the safety, tolerability, pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin lymphoma. Objectives: 1. To determine the safety and tolerability of increasing doses of single cycles of AFM13 monotherapy. 2. To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13; whichever is reached first. 3. To define the pharmacokinetic profile of AFM13. 4. To analyse immunological markers e.g. ADCC (Antibody dependent cell mediated cytotoxicity), NK (Natural killer) cell activity, complement activation and depletion, and cytokine release. 5. To assess the immunogenicity of AFM13. 6. To assess the activity of AFM13.